On 21 March 2026, Beijing Grand Jiuhe Pharmaceutical Co., Ltd., the respiratory division of Grand Pharma (0512.HK), held a launch event for 莱特灵®/Ryaltris® (olopatadine hydrochloride and mometasone furoate monohydrate nasal spray), a globally innovative, first-in-class drug.
The launch event will be held in a hybrid format, with simultaneous activities taking place across six locations (Wuhan, Beijing, Shanghai, Guangzhou, Chongqing and Nanjing). Over 60 leading experts in the fields of otolaryngology, pediatrics and allergy from both China and abroad, as well as more than 350 distinguished scholars from 268 regional medical centers, have been invited to witness the rollout of this innovative therapy.
Over 60 leading experts in the fields of otolaryngology, pediatrics and allergy from both China and abroad, as well as more than 350 distinguished scholars from 268 regional medical centers, have been invited to witness the rollout of this innovative therapy.
